Zacks Research Brokers Boost Earnings Estimates for PBH

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Stock analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, June 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.19 per share for the quarter, up from their previous forecast of $1.18. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.73 EPS and Q4 2027 earnings at $1.25 EPS.

Other analysts also recently issued reports about the company. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.27 during trading on Wednesday, hitting $83.37. The stock had a trading volume of 362,361 shares, compared to its average volume of 298,971. The company has a 50 day moving average price of $83.93 and a 200-day moving average price of $82.51. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of 19.43, a P/E/G ratio of 2.50 and a beta of 0.45. Prestige Consumer Healthcare has a one year low of $64.94 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The firm's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 EPS.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kestra Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $27,000. CIBC Private Wealth Group LLC raised its holdings in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the 1st quarter worth $38,000. Headlands Technologies LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $40,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.